TEK Human

TIE-1 and TIE-2/Tek are receptor tyrosine kinases (RTKs) primarily found on endothelial and hematopoietic progenitor cells. They play crucial roles in angiogenesis, vasculogenesis, and hematopoiesis. TIE-1 is a 1122 amino acid protein with unique structural characteristics, including immunoglobulin-like and epidermal growth factor (EGF)-like domains. TIE-2 binds to angiopoietin-1 (Ang1) and angiopoietin-2 (Ang2), with Ang2 potentially acting as an antagonist to Ang1. Disruptions in these pathways, such as Ang2 overexpression or Ang1/Tie-1 deficiency, can lead to angiogenic defects.

Recombinant human TEK, expressed in Sf9 insect cells using baculovirus, is a glycosylated polypeptide chain with a molecular weight of approximately 107.9 kDa (appears as 100-150 kDa on SDS-PAGE). It encompasses amino acids 23-748 of the TEK protein and includes a C-terminal 239 amino acid hIgG-His tag for purification.

The TEK protein is supplied in a solution at a concentration of 0.5 mg/ml, containing 10% glycerol and Phosphate Buffered Saline (pH 7.4).

For short-term storage (up to 4 weeks), store the protein solution at 4°C. For extended storage, freeze the solution at -20°C. To ensure stability during long-term storage, consider adding a carrier protein like HSA or BSA (0.1%). Avoid repeated freeze-thaw cycles to maintain protein integrity.

The purity of the TEK protein is greater than 90% as determined by SDS-PAGE analysis.

The biological activity of TEK is determined by its binding ability in a functional ELISA. The ED50 value is less than or equal to 1 µg/ml, indicating its potency in this assay.

TEK Receptor Tyrosine Kinase, Tyrosine Kinase With Ig And EGF Homology Domains-2, Tunica Interna Endothelial Cell Kinase, Tyrosine-Protein Kinase Receptor TIE-2, Tyrosine-Protein Kinase Receptor TEK, TEK Tyrosine Kinase, Endothelial, Endothelial Tyrosine Kinase, EC 2.7.10.1, VMCM1, VMCM, TIE2, Venous Malformations, Multiple Cutaneous And Mucosal, Angiopoietin-1 Receptor, CD202b Antigen, EC 2.7.10, P140 TEK, CD202B, GLC3E, TIE-2, HTIE2.

AMDLILINSL PLVSDAETSL TCIASGWRPH EPITIGRDFE ALMNQHQDPL EVTQDVTREW AKKVVWKREK ASKINGAYFC EGRVRGEAIR IRTMKMRQQA SFLPATLTMT VDKGDNVNIS FKKVLIKEED AVIYKNGSFI HSVPRHEVPD ILEVHLPHAQ PQDAGVYSAR YIGGNLFTSA FTRLIVRRCE AQKWGPECNH LCTACMNNGV CHEDTGECIC PPGFMGRTCE KACELHTFGR TCKERCSGQE GCKSYVFCLP DPYGCSCATG WKGLQCNEAC HPGFYGPDCK LRCSCNNGEM CDRFQGCLCS PGWQGLQCER EGIPRMTPKI VDLPDHIEVN SGKFNPICKA SGWPLPTNEE MTLVKPDGTV LHPKDFNHTD HFSVAIFTIH RILPPDSGVW VCSVNTVAGM VEKPFNISVK VLPKPLNAPN VIDTGHNFAV INISSEPYFG DGPIKSKKLL YKPVNHYEAW QHIQVTNEIV TLNYLEPRTE YELCVQLVRR GEGGEGHPGP VRRFTTASIG LPPPRGLNLL PKSQTTLNLT WQPIFPSSED DFYVEVERRS VQKSDQQNIK VPGNLTSVLL NNLHPREQYV VRARVNTKAQ GEWSEDLTAW TLSDILPPQP ENIKISNITH SSAVISWTIL DGYSISSITI RYKVQGKNED QHVDVKIKNA TITQYQLKGL EPETAYQVDI FAENNIGSSN PAFSHELVTL PESQAPADLG GGKMLLLEPK SCDKTHTCPP CPAPELLGGP SVFLFPPKPK DTLMISRTPE VTCVVVDVSH EDPEVKFNWY VDGVEVHNAK TKPREEQYNS TYRVVSVLTV LHQDWLNGKE YKCKVSNKAL PAPIEKTISK AKGQPREPQV YTLPPSRDEL TKNQVSLTCL VKGFYPSDIA VEWESNGQPE NNYKTTPPVL DSDGSFFLYS KLTVDKSRWQ QGNVFSCSVM HEALHNHYTQ KSLSLSPGKH HHHHH.